Considerations for the real‐world management of ARIA from the aducanumab phase 3 studies EMERGE and ENGAGE
Patrick Burkett(Biogen (United States)), Samantha Budd Haeberlein(Biogen (United States)), Karen Smirnakis(Biogen (United States)), Derk D. Purcell(BioClinica (United States)), Sami Fam(Biogen (United States)), Carmen Castrillo‐Viguera(Biogen (United States)), Kimberly Umans(Biogen (United States)), Jerome Barakos(Sutter Health), Spyros Chalkias(Moderna Therapeutics (United States))
Cited by 1
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
|New England Journal of Medicine|2022|649